Mogamulizumab Tops Standard of Care for CTCL [News in Brief]

Anti-CCR4 antibody significantly improves progression-free survival compared with vorinostat for type of non–Hodgkin lymphoma.

from Cancer via ola Kala on Inoreader http://ift.tt/2lRLX0l
via IFTTT